From: Bortezomib induced peripheral neuropathy and single nucleotide polymorphisms in PKNOX1
Parameter | |
---|---|
Patients, n | 88 |
Gender, n (%) Male Female | 64 (73) 24 (27) |
Age at diagnosis, median, years (range) Age at bortezomib start, median, years (range) | 61 (30–79) 62 (30–79) |
Subtype, n (%) IgG Non-IgG LC | 46 (52) 18 (21) 24 (27) |
Cytogenetics, n (%) High-risk# Standard-risk | 18 (20) 70 (80) |
Patient groups, n (%) Bortezomib naïve under ongoing bortezomib treatment s.p. bortezomib treatment§ | 10 (11) 37 (42) 41 (47) |
Prior treatment, n (%) Immunomodulatory drugs Lenalidomide Pomalidomide Thalidomide Proteasome inhibitors other than bortezomib Carfilzomib Ixazomib Monoclonal antibodies Daratumumab Elotuzumab | 48 (55) 26 (30) 27 (31) 22 (25) 5 (6) 65 (74) 9 (10) |
Pre-existing peripheral neuropathy, n (%) Idiopathic sensory-motor polyneuropathy Diabetic neuropathy Sensory-motor deficits after intracranial hemorrhage | 3 (3) 1 (1) 1 (1) |
Prevalence of BIPN, n (%) No BIPN BIPN without pain Painful BIPN | 15 (17) 39 (44) 34 (39) |
BIPN grade, n (%) No BIPN Grade 1 Grade 2 Grade 3 | 15 (17) 44 (50) 26 (30) 3 (3) |